Arcus Biosciences (NYSE:RCUS) Earns “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Arcus Biosciences (NYSE:RCUS) in a report released on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the stock.

RCUS has been the topic of a number of other research reports. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd. Barclays boosted their target price on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Finally, Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $34.13.

Arcus Biosciences Trading Up 8.4 %

Shares of Arcus Biosciences stock opened at $17.85 on Wednesday. The firm has a fifty day simple moving average of $16.61 and a 200-day simple moving average of $16.06. Arcus Biosciences has a 1-year low of $12.95 and a 1-year high of $20.31. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -5.67 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 44.90%. The business had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same period in the previous year, the company earned ($0.94) earnings per share. Arcus Biosciences’s revenue for the quarter was up 50.0% on a year-over-year basis. As a group, research analysts predict that Arcus Biosciences will post -3.25 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Headlands Technologies LLC bought a new stake in Arcus Biosciences in the 1st quarter valued at $59,000. Innealta Capital LLC acquired a new stake in shares of Arcus Biosciences in the 2nd quarter valued at $66,000. Point72 DIFC Ltd acquired a new stake in shares of Arcus Biosciences in the 2nd quarter valued at $83,000. Quest Partners LLC boosted its stake in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in shares of Arcus Biosciences by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 10,846 shares of the company’s stock valued at $205,000 after purchasing an additional 746 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.